Solara Active Pharma Sciences Limited (SOLARA) reports a 33% YoY revenue growth to INR 4,178 Mn and EBITDA more than doubling in Q2 FY27.
Solara Active Pharma Sciences Limited (SOLARA) reports Q1’27 earnings with base business revenues up 24% YoY, EBITDA up 8% despite geopolitical impacts.
Solara Active Pharma Sciences Limited (NSE: SOLARA) reports strong Q4’26 earnings with 40% YoY growth, driven by robust base business despite challenges in Ibuprofen segment.